Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd(University of Cincinnati), Richard R. Furman(Cornell University), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Amy J. Johnson(Ouranos), Wayne Rothbaum, Raquel Izumi, Deborah M. Stephens(University of North Carolina at Chapel Hill), Jesse McGreivy(Pharmacyclics (United States)), John M. Pagel(University of Washington), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Bonnie K. Harrington(Michigan State University), Todd Covey(Unknown), Maria Fardis(Pharmacyclics (United States)), Brian J. Lannutti(Fate Therapeutics (United States)), Farrukh T. Awan(The University of Texas Southwestern Medical Center), Ahmed Hamdy(Pharmacyclics (United States)), Jorge Chaves(Northwest Medical Specialties), Anna Schuh(University of Oxford), Jacqueline C. Barrientos(Mount Sinai Medical Center), Allard Kaptein, Paolo Ghia(Vita-Salute San Raffaele University), William G. Wierda(University of Maryland, Baltimore), Thomas G. Diacovo, Xiaolin Wang(University of Science and Technology of China), Jane Huang(University of Southern California), Jeffrey A. Jones(The Ohio State University), Dave Johnson, Susan O’Brien(University of California, Irvine)
Cited by 890
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k